Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models

INTRODUCTION: The KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRAS(G12C) protein have been developed and demonstrate clinical response rates of 37-43%. Importantly, these agents fail to generate durable th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sisler, Daniel J., Hinz, Trista K., Le, Anh T., Kleczko, Emily K., Nemenoff, Raphael A., Heasley, Lynn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945252/
https://www.ncbi.nlm.nih.gov/pubmed/36845684
http://dx.doi.org/10.3389/fonc.2023.1094123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945252/
https://www.ncbi.nlm.nih.gov/pubmed/36845684
http://dx.doi.org/10.3389/fonc.2023.1094123

Ejemplares similares